Targeted Therapy and Oral Chemotherapy as Maintenance Treatment in Pediatric Very‐High‐Risk and High‐Risk Rhabdomyosarcoma: A Retrospective Study of Efficacy and Safety
- 26 June 2026
- journal article
- Published by Wiley in International Journal of Cancer
- Vol. 159 (11) , 2778-2790
Abstract
Maintenance therapy (MT) and targeted drugs have improved the survival of patients with high‐risk rhabdomyosarcoma (RMS) in clinical trials. However, there are limited data concerning targeted drugs and oral chemotherapy for MT in pediatric patients with very‐high‐risk (VHR) and high‐risk (HR) RMS. Here, we evaluated the safety and effectiveness of these regimens and aimed to identify circulating tumor DNA (ct‐DNA) markers associated with prognosis. We retrospectively retrieved data for 102 pediatric patients with VHR or HR RMS who underwent MT at Sun Yat‐sen University Cancer Center from January 2011 to March 2025 involving targeted drugs plus oral chemotherapy (subgroup 1); targeted drugs (subgroup 2); and oral chemotherapy (subgroup 3). Ct‐DNA markers were examined throughout treatment and at follow‐up. Subgroups 1 and 2 comprised 14 and seven VHR RMS patients, respectively, and subgroup 3 consisted of 39 VHR and 42 HR RMS patients. With a median follow‐up of 32 months, no significant differences among subgroups in duration of remission ( p = 0.56) or 2‐year event‐free survival ( p = 0.78) were observed. PAX–FOXO1 fusion ( p = 0.01), CDK4 mutation ( p = 0.02), and TP53 mutation ( p = 0.02) were independently associated with unfavorable duration of remission. No grade 3 or higher treatment‐related adverse events were observed. MT with targeted drugs shows comparable efficacy in VHR and HR pediatric RMS patients, with manageable adverse reactions. Longitudinal ct‐DNA testing could guide treatment decision‐making and prognostic stratification for these patients.Keywords
Funding Information
- National Natural Science Foundation of China (82573596)
This publication has 32 references indexed in Scilit:
- Impact of maintenance treatment on male gonadal function in patients treated for localized rhabdomyosarcoma in RMS2005 trial in FranceCancer, 2025
- Safety and feasibility of anlotinib in children with high risk, recurrent or refractory sarcomas: an open-label, single-centre, single-arm, phase Ia/Ib trialeClinicalMedicine, 2025
- Maintenance therapy with trofosfamide, idarubicin and etoposide in patients with rhabdomyosarcoma and other high-risk soft tissue sarcomas (CWS-2007-HR): a multicentre, open-label, randomised controlled phase 3 trialeClinicalMedicine, 2024
- Significance of fusion status, Oberlin risk factors, local and maintenance treatment in pediatric and adolescent patients with metastatic rhabdomyosarcoma: Data of the European Soft Tissue Sarcoma Registry SoTiSaRPediatric Blood & Cancer, 2023
- Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trialeClinicalMedicine, 2023
- An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trialsPediatric Blood & Cancer, 2022
- Anlotinib, Vincristine, and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy: A Two-Cohort, Phase Ib/II TrialThe Oncologist, 2021
- Association of circulating tumor DNA from the cerebrospinal fluid with high‐risk CNS involvement in patients with diffuse large B‐cell lymphomaClinical and Translational Medicine, 2021
- Anlotinib: First Global ApprovalDrugs, 2018
- Fusion status in patients with lymph node‐positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)Cancer, 2018